Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2014 ASCO Annual Meeting

30 May - 3 Jun 2014
McCormick Place, Chicago, United States of America
Melanoma live: Making patient-focused therapy decisions
Prof Dirk Schadendorf; Dr Paul Nathan; Prof Georgina Long
Melanoma live: Making patient-focused therapy decisions ( Prof Dirk Schadendorf; Dr Paul Nathan; Prof Georgina Long )
1 Aug 2014
LHRH analogue goserelin helps preserve fertility among women undergoing chemo f...
Dr Halle Moore - Taussig Cancer Institute, Cleveland, USA
LHRH analogue goserelin helps preserve fertility among women undergoing chemo for hormone receptor-negative breast cancer ( Dr Halle Moore - Taussig Cancer Institute, Cleveland, USA )
12 Jun 2014
KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-lin...
Prof Marc Peeters - University of Antwerp, Antwerp, Belgium
KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-line treatment of mCC ( Prof Marc Peeters - University of Antwerp, Antwerp, Belgium )
2 Jun 2014
HPV-targeted adoptive T Cell therapy for advanced cervical cancer
Dr Christian Hinrichs - Center for Cancer Research, Bethesda, USA
HPV-targeted adoptive T Cell therapy for advanced cervical cancer ( Dr Christian Hinrichs - Center for Cancer Research, Bethesda, USA )
2 Jun 2014
Summary of breaking prostate news from ASCO 2014
Prof Eleni Efstathiou and Prof Gordon McVie
Summary of breaking prostate news from ASCO 2014 ( Prof Eleni Efstathiou and Prof Gordon McVie )
2 Jun 2014
PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against met...
Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US
PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against metastatic melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US )
2 Jun 2014
Ipilimumab and nivolumab achieves long-term survival in advanced melanoma
Prof Mario Sznol - Yale Cancer Center, New Haven, USA
Ipilimumab and nivolumab achieves long-term survival in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )
2 Jun 2014
Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III mel...
Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands
Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma ( Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands )
2 Jun 2014
HPV-targeted adoptive T Cell therapy may provide a new personalised strategy for...
Dr Christian S. Hinrichs - Center for Cancer Research, Bethesda, US
HPV-targeted adoptive T Cell therapy may provide a new personalised strategy for advanced cervical cancer ( Dr Christian S. Hinrichs - Center for Cancer Research, Bethesda, US )
2 Jun 2014
Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for adv...
Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )
2 Jun 2014
Comment: Adjuvant ipilimumab in high-risk melanoma
Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )
2 Jun 2014
Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma
Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )
2 Jun 2014
Comment: Immunotherapy combo increases median survival in advanced melanoma
Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
Comment: Immunotherapy combo increases median survival in advanced melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )
2 Jun 2014
Success for ipilimumab and nivolumab combo in advanced melanoma
Prof Mario Sznol - Yale Cancer Center, New Haven, USA
Success for ipilimumab and nivolumab combo in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )
2 Jun 2014
Comment: CALGB/SWOG 80405 study on chemo combos in colorectal
Prof Marc Peeters - University of Antwerp, Antwerp, Belgium
Comment: CALGB/SWOG 80405 study on chemo combos in colorectal ( Prof Marc Peeters - University of Antwerp, Antwerp, Belgium )
2 Jun 2014
Discontinuing statins near the end of life is safe, improves patient quality of ...
Prof Amy P. Abernethy - Duke University School of Medicine, Durham, USA
Discontinuing statins near the end of life is safe, improves patient quality of life ( Prof Amy P. Abernethy -  Duke University School of Medicine, Durham, USA )
2 Jun 2014
Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid can...
Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France
Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )
2 Jun 2014
Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial...
Prof Thomas Powles - Barts Health, London, UK
Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer ( Prof Thomas Powles - Barts Health, London, UK )
2 Jun 2014
Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lym...
Prof Max Topp - Würzburg University Hospital, Würzburg, Germany
Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )
2 Jun 2014
Regorafenib shows early promise in colorectal candidates unable to undergo chemo
Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain
Regorafenib shows early promise in colorectal candidates unable to undergo chemo ( Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain )
2 Jun 2014
Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck can...
Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA
Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers ( Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA )
2 Jun 2014
ASCO 2014 roundup
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
2 Jun 2014
Lapatinib not found to be beneficial in head and neck cancer with high risk of r...
Prof Kevin Harrington - Institute of Cancer Research, London, UK
Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )
2 Jun 2014
Addition of docetaxel to initial hormone therapy substantially improves survival...
Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA )
2 Jun 2014
T-VEC injections into melanoma lesions show significant response rate
Prof Kevin Harrington - Institute of Cancer Research, London, UK
T-VEC injections into melanoma lesions show significant response rate ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )
2 Jun 2014
Impact of cytotoxics on pregnancy needs to be better understood
Dr Shahid Gilani - University Hospital of North Staffordshire, Stoke-on-Trent, U...
Impact of cytotoxics on pregnancy needs to be better understood ( Dr Shahid Gilani - University Hospital of North Staffordshire, Stoke-on-Trent, UK )
2 Jun 2014
First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survi...
Dr Ramon Salazar - L'Hospitalet de Llobregat, Barcelona, Spain
First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer ( Dr Ramon Salazar - L'Hospitalet de Llobregat, Barcelona, Spain )
2 Jun 2014
Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- sta...
Dr Edith Perez - Mayo Clinic, Rochester, USA
Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer ( Dr Edith Perez - Mayo Clinic, Rochester, USA )
1 Jun 2014
Genomic sequencing helps identify best candidates for adjuvant chemo in colorect...
Dr Ramon Salazar - L'Hospitalet de Llobregat, Barcelona, Spain
Genomic sequencing helps identify best candidates for adjuvant chemo in colorectal cancer ( Dr Ramon Salazar - L'Hospitalet de Llobregat, Barcelona, Spain )
1 Jun 2014
Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014
Prof Franco Cavalli, Prof Gordon McVie
Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014 ( Prof Franco Cavalli, Prof Gordon McVie )
1 Jun 2014
Addition of docetaxel to initial hormone therapy substantially improves survival...
Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2014
First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survi...
Dr Alan Venook; Prof Gordon McVie
First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer ( Dr Alan Venook; Prof Gordon McVie )
1 Jun 2014
ASCO 2014: Advances in prostate cancer discussion
Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki
ASCO 2014: Advances in prostate cancer discussion ( Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki )
1 Jun 2014
Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stag...
Dr Edith Perez - Mayo Clinic, Rochester, USA
Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer ( Dr Edith Perez - Mayo Clinic, Rochester, USA )
1 Jun 2014
First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide...
Dr Alan Venook - UCSF, San Francisco, USA
First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer ( Dr Alan Venook - UCSF, San Francisco, USA )
1 Jun 2014
Addition of docetaxel to initial hormone therapy substantially improves survival...
Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2014
Adjuvant exemestane more effective than tamoxifen when combined with ovarian fun...
Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switz...
Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )
1 Jun 2014
Adjuvant exemestane is more effective than tamoxifen when combined with ovarian ...
Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switz...
Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )
1 Jun 2014
Comment: Advances in breast cancer presented at ASCO 2014
Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland
Comment: Advances in breast cancer presented at ASCO 2014 ( Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland )
1 Jun 2014
Comment: Advances in lung cancer presented at ASCO 2014
Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland
Comment: Advances in lung cancer presented at ASCO 2014 ( Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland )
1 Jun 2014
Medyczne nowości w raku gruczołu krokowego
Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland
Medyczne nowości w raku gruczołu krokowego ( Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland )
1 Jun 2014
Ramucirumab plus docetaxel extends survival in advanced NSCLC
Dr Maurice Pérol - Centre Léon Bérard, Lyon, France
Ramucirumab plus docetaxel extends survival in advanced NSCLC ( Dr Maurice Pérol - Centre Léon Bérard, Lyon, France )
31 May 2014
Targeted drug combo, cediranib plus olaparib, significantly increases progressio...
Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA
Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer ( Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA )
31 May 2014
Ibrutinib significantly delays disease progression and extends survival in resis...
Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014
Lenvatinib yields high response rates and delays progression in radioiodine-resi...
Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France
Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )
31 May 2014
Second-line treatment with ramucirumab plus docetaxel extends survival in advan...
Dr Maurice Pérol - Centre Léon Bérard, Lyon, France
Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC ( Dr Maurice Pérol - Centre Léon Bérard, Lyon, France )
31 May 2014
Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer
Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA
Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer ( Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA )
31 May 2014
Ibrutinib significantly delays disease progression and extends survival in resis...
Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014